[123I]MIBG is a better early marker of anthracycline cardiotoxicity than [18F]FDG: a preclinical SPECT/CT and simultaneous PET/MR study

Figures

• 

  Fig. 1. Representative MR images in short axis view. End-diastolic frame is represented on the upper panel and end-systolic frame on the lower panel. Left panel: MR images obtained in control rats. Right panel: MR images obtained in doxorubicin-treated rats. Red arrows indicate ascite/pleural effusion

• 

  Fig. 2. Cardiac function parameters measured every 2 weeks on cardiac cine MR images. a Left ventricle end-systolic volume; b left ventricle end-diastolic volume; c, d, respectively, left and right ventricle ejection fractions. LV ESV Left ventricle end-systolic volume, LV EDV left ventricle end-diastolic volume, LVEF left ventricle ejection fraction, RVEF right ventricle ejection fraction. Data are expressed as mean ± SEM

• 

  Fig. 3. Evaluation of cardiac morphology at the end of the 6 weeks of experimental protocol. a Weight of the heart at the time of harvesting and heart-to-body weight ratio. b Histomorphometry measurements of left ventricular area and left ventricular thickness measured on Hematoxylin–eosin stained cardiac slices. LV Left ventricle. Data are expressed as mean ± SEM. c Representative full view of cardiac morphology of Hematoxylin–eosin stained cardiac slices in control (upper panel) and doxorubicin-treated rats (lower panel)

• 

  Fig. 4. Evaluation of cardiac [18F]FDG uptake in vehicle and doxorubicin-treated rats measured on PET images. Cardiac [18F]FDG uptake monitoring during the 6 weeks of experimental protocol. Data are expressed as % ID/g related to control group (a) and %ID/g (b) and as mean ± SEM. p values presented on graphs are comparisons between control and doxorubicin groups c. Representative cardiac-centered coronal views of [18F]FDG PET images in control (upper panel) and doxorubicin-treated rats (lower panel) obtained at 6 weeks

• 

  Fig. 5. Evaluation of cardiac [123I]MIBG uptake in vehicle and doxorubicin-treated rats measured on SPECT images. a, b Cardiac [123I]MIBG uptake monitoring during the 6 weeks of experimental protocol. Data are expressed as heart to mediastinum (H to M) ratio related to control group (a) and H to M ratio (b) and as mean ± SEM. p values presented on graphs are comparisons between control and doxorubicin groups. c Representative cardiac-centered coronal views of [123I]MIBG SPECT-CT images in control (upper panel) and doxorubicin-treated rats (lower panel) obtained at 6 weeks

• 

  Fig. 6. Correlation between LV ejection fraction and [18F]FDG cardiac uptake (a) or [123I]MIBG cardiac uptake (b). Data were obtained using Pearson correlation. Graphs represent linear regression line and 95% confidence interval (dotted line). H to M: heart to mediastinum